CLXT - Calyxt exploring strategic alternatives

• Plant-based synthetic biology company Calyxt, Inc. ( NASDAQ: CLXT ) announced Thursday that the company is exploring potential strategic alternatives to maximize shareholder value.
• As part of the process, the CLXT board is weighing options, including the methods for financing, sale of assets, licensing, and business combinations such as a reverse merger, merger, or other transactions.
• The company has selected Canaccord Genuity as its financial advisor and Sidley Austin as its legal counsel to support the process.
• CLXT did not provide a timeline to complete the process and will update its progress only in case of a definitive agreement and if the board considers such disclosure necessary.
• CLXT shares have lost more than 93% over the past 12 months, as shown in this graph.

For further details see: